Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Efficacy: ZOL vs No ZOL<br />
• Adding zoledronic acid to endocrine therapy<br />
significantly prolonged DFS and RFS vs endocrine<br />
therapy alone<br />
–� Risk of DFS events by 36% (HR = 0.64; P = .012)<br />
–� Risk of RFS events by 35% (HR = 0.65; P = .014)<br />
• Zoledronic acid produced a trend toward improved<br />
OS (HR = 0.60; P = .10)<br />
• Trend towards a reduction in bone metastases with<br />
zoledronic acid<br />
– 16 ZOL vs 23 No ZOL (HR = 0.68; P = .224)<br />
22
Change language